HIV-1 Integrase Inhibitors That Are Active against Drug-Resistant Integrase Mutants

The currently recommended first-line therapy for HIV-1-infected patients is an integrase (IN) strand transfer inhibitor (INSTI), either dolutegravir (DTG) or bictegravir (BIC), in combination with two nucleoside reverse transcriptase inhibitors (NRTIs). Both DTG and BIC potently inhibit most INSTI-r...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Antimicrob Agents Chemother
Hlavní autoři: Smith, Steven J., Zhao, Xue Zhi, Passos, Dario Oliveira, Lyumkis, Dmitry, Burke, Terrence R., Hughes, Stephen H.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society for Microbiology 2020
Témata:
Antiviral Agents
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7449158/
https://ncbi.nlm.nih.gov/pubmed/32601157
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00611-20
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky